Agonist News and Research

RSS

Study: Potential biomarker in the blood predicts sudden cardiac deaths

The discovery of a biomarker readily measured in blood could be a significant step towards preventing sudden deaths.

28 Feb 2024

Novel insights into pathologies of diabetic cardiomyopathy, hippocampal neurotoxicity, and Alzheimer’s

DCM is the leading cause of heart failure in patients with chronic diabetes. However, the underlying mechanisms of DCM are poorly understood, and treatment options are limited.

26 Feb 2024

Yale School of Medicine secures $575,000 grant for Long COVID research

Yale School of Medicine and its Center for Infection & Immunity (CII) are receiving a $575,000 grant from PolyBio Research Foundation to fund Long COVID research.

23 Feb 2024

Delta opioid receptor agonist reduces anxiety-like behavior in mice

Anxiety-related disorders can have a profound impact on the mental health and quality of life of affected individuals.

22 Feb 2024

Intravenous DMT shows promise in reducing depression symptoms, study reveals

A study in Scientific Reports shows intravenous DMT can significantly reduce depression severity in healthy volunteers, highlighting its potential as a therapeutic psychedelic intervention for mental health disorders.

8 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024

Breakthrough obesity treatments on the horizon, rivaling surgery's success

New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric surgery's effectiveness.

4 Feb 2024

Deep brain stimulation may improve quality of life in Parkinsons disease

Researchers compare the impact of medication alone or deep brain stimulation of the subthalamic nuclei in quality of life in Parkinson's patients.

22 Jan 2024

Diabetes drugs may help curb alcohol dependence

In social media posts on the community network Reddit, users reported reduced cravings for alcohol when taking drugs intended to treat Type 2 diabetes and obesity.

8 Jan 2024

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

4 Jan 2024

Scientists design non-hallucinogenic psychedelic treatments potentially accelerating research on mental health benefits

Researchers identified 5-hydroxytryptamine 2A (5-HT2A) receptor (5-HT2AR) signaling pathways associated with psychedelic potential.

19 Dec 2023

Only 1 in 18 people with opioid use disorder get effective treatment after overdose

In the week following any hospital visit for an overdose, only 1 in 18 people with opioid use disorder begin a treatment known to be highly effective in reducing illness and deaths, according to new research in CMAJ (Canadian Medical Association Journal).

18 Dec 2023